A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Inclusion Criteria:

• Age ≥ 18 years old at the time of enrolment.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Expected Survival of ≥ 12 weeks.

• Diagnosed as R/R cHL according to Lugano 2014 criteria.

• Has progressed on treatment with PD-1/L1 inhibitior therapy.

• Has adequate organ function.

• All female and male subjects of reproductive potential must agree to use aneffective method of contraception from the start of screening until 120 days afterthe last dose of study treatment.

Exclusion Criteria:

• Diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) or gray zonelymphoma.

• Central nervous system (CNS) lymphoma involvement.

• Known history of human T-cell leukemia virus type 1 (HTLV-1) infection.

• Autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigenreceptor T cell immunotherapy (CAR-T) within 90 days prior to the first dose ofstudy treatment.

• Known history of allogeneic organ transplantation or allogeneic hematopoietic stemcell transplantation (allo-HSCT).

• Previous use of any agents targeting the CD47-SIRPα pathway, LAG-3 pathway, orsimilar targets.

• Has other malignancies within 3 years prior to the first dose or residual lesionsfrom other malignancies diagnosed more than 3 years ago.

• Has an active autoimmune disease requiring systemic treatment within 2 years priorto the first dose.

• History of active or previously confirmed inflammatory bowel disease.

• History of interstitial lung disease requiring corticosteroid therapy, or currentinterstitial lung disease.

• Has known active Hepatitis B or Hepatitis C.

• Unresolved toxicity from previous anti-tumor treatment.

• Uncontrolled comorbidities.